Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome (original) (raw)
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis
Liliana Mendez
Clinical Journal of the American Society of Nephrology, 2018
View PDFchevron_right
Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review
A. Contis
Clinical Rheumatology, 2016
View PDFchevron_right
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study
Berenice Perez Mendoza
Arthritis Research & Therapy, 2006
View PDFchevron_right
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Paul Emery
Arthritis & Rheumatism, 2012
View PDFchevron_right
Rituximab Therapy in Lupus Nephritis: Current Clinical Evidence
Pilar Brito-Zerón
Clinical Reviews in Allergy & Immunology, 2011
View PDFchevron_right
Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus
Fausta Catapano
Nephrology Dialysis Transplantation, 2010
View PDFchevron_right
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts
Javier Rascón
Autoimmunity Reviews
View PDFchevron_right
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Kyriakos Kirou
Arthritis & Rheumatology, 2020
View PDFchevron_right
Rituximab: the Lupus Journey
Lucía Ramos
Current Treatment Options in Rheumatology, 2015
View PDFchevron_right
Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
Mark Cragg
Rheumatology, 2021
View PDFchevron_right
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
Dr. Dr. Marc J Weidenbusch, MME
Nephrology Dialysis Transplantation, 2013
View PDFchevron_right
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus including lupus nephritis who are refractory to conventional therapy
Yoshiya Tanaka
Modern rheumatology / the Japan Rheumatism Association, 2015
View PDFchevron_right
Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study
B. Gallelli
Annals of the Rheumatic Diseases, 2012
View PDFchevron_right
Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression
Therese Jungraithmayr
Pediatric Nephrology, 2005
View PDFchevron_right
Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis
Ying Ying Leung, Edmund Li
Rheumatology (Oxford, England), 2009
View PDFchevron_right
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Analia Alvarez
Annals of the Rheumatic Diseases, 2021
View PDFchevron_right
Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
Chang-keun Lee
Journal of Rheumatic Diseases
View PDFchevron_right
Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin
Carlo Perricone
Autoimmunity Reviews, 2010
View PDFchevron_right
Treatment for refractory lupus nephritis: Rituximab vs triple target therapy
Roberto Ríos
Autoimmunity Reviews, 2019
View PDFchevron_right
Treating severe systemic lupus erythematosus with rituximab. An open study
Lilia Cueva
2009
View PDFchevron_right
Pragmatic treatment of patients with Systemic Lupus Erythematosus with rituximab: Long-term effects on serum immunoglobulins
Maria Leandro
Arthritis care & research, 2016
View PDFchevron_right
Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis
Yves Renaudineau
2013
View PDFchevron_right
Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future
Michael Walsh
Kidney International, 2007
View PDFchevron_right
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
A. Sanchez-atrio, Rosario García-Vicuña
Lupus, 2012
View PDFchevron_right
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
Megan Griffith
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
P. Caroline Gordon
Arthritis & Rheumatism, 2010
View PDFchevron_right
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
Asad Zoma
Rheumatology (Oxford, England), 2017
View PDFchevron_right
SaO041PROSPECTIVE LONG TERM FOLLOW UP OF THE RITUXILUP STEROID SPARING REGIMEN IN LUPUS NEPHRITIS
Megan Griffith
Nephrology Dialysis Transplantation, 2015
View PDFchevron_right
Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review
Thierry Schaeverbeke
Seminars in Arthritis and Rheumatism, 2014
View PDFchevron_right